Journal Article Summary
The article discusses the development of GS-5245, also known as Obeldesivir, which is an oral prodrug designed to treat COVID-19. This research is significant because the ongoing COVID-19 pandemic has highlighted the need for effective antiviral treatments, especially as new variants of the virus continue to emerge. Current treatments, such as remdesivir, require intravenous administration, which limits their accessibility and convenience for patients. The study aims to provide a more practical oral option that can effectively combat SARS-CoV-2.
The researchers conducted experiments using African green monkeys to evaluate the antiviral efficacy of GS-5245. They found that this new prodrug significantly improved the delivery of its active form, GS-441524, leading to effective inhibition of the virus. The study showed that GS-5245 had low toxicity and was able to reduce viral loads in the monkeys, suggesting that it could be a promising treatment option for COVID-19. The estimated clinical dose for humans is projected to be around 350-400 mg taken twice daily, and the drug appears to remain effective against various SARS-CoV-2 variants.
However, there are limitations to this study. The findings are based on animal models, and further research is needed to confirm the safety and efficacy of GS-5245 in humans. Patients should consult with healthcare professionals about the potential risks and benefits of new treatments like GS-5245, especially considering the evolving nature of COVID-19 and the emergence of new variants. It is crucial for patients to stay informed and discuss any new treatment options with their healthcare providers to ensure safe and effective care.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication. Always consult a licensed healthcare professional before using a medical device.
Article Cited
- Mackman Richard L., Kalla Rao V., Babusis Darius, Pitts Jared, Barrett Kimberly T., Chun Kwon, Du Pont Venice, Rodriguez Lauren, et al.. Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys. Journal of medicinal chemistry 2023. DOI: 10.1021/acs.jmedchem.3c00750. PMID: 37596939. PMCID: PMC11556372.
Featured Pill Pals Product
Pill Pals - Pill Cutter, Crusher, Splitter, and Holder (3 in 1) --- Three in One --- Dukal --- Over The Counter
Pill Pals – Pill Cutter, Crusher, Splitter, and Holder (3 in 1) — Three in One — Dukal — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
